Kauppi Juha, Räsänen Jari, Sihvo Eero, Huuhtanen Riikka, Nelskylä Kaisa, Salo Jarmo
Department of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Central Hospital, HUS, Haartmaninkatu 4, P. O. Box 340, Helsinki, 00029, Finland.
Surg Endosc. 2015 Sep;29(9):2614-9. doi: 10.1007/s00464-014-3978-8. Epub 2014 Dec 6.
We compared oncologic and surgical outcome between minimally invasive esophagectomy (MIE) and the Ivor Lewis-type open approach (OE) in the treatment of locally advanced esophageal adenocarcinoma (EAC).
Of 284 patients undergoing surgery for EAC between 2003 and 2013, the 153 selected with locally advanced EAC were 74 MIEs and 79 OEs [median age, 66 for MIE, 63 for OE (p = 0.009)]. Neoadjuvant therapy was given to 82% of MIEs and 78% of OEs. In the OE group, 86% was male, and in the MIE group, 78%. Data assessed were oncologic, intraoperative, and postoperative.
Mortality at 30 days was 3% for MIE and 1% for OE; and 90-day mortality was 4% for MIE and 5% for OE. The complication rate for MIE was 50%, and 60% for OE (p = 0.181). The pneumonia rate was 18% for MIE and 19% for OE; leak rate was 7% for MIE and 6% for OE; conduit necrosis was 0 for MIE and 3% for OE; and rate of airway-conduit fistula was 3% for MIE and 1 % for OE. Median blood loss (MIE 300 vs. OE 800, p < 0.0001), overall stay (MIE 13 vs. OE 14, p = 0.040), and harvested lymph nodes (MIE 20 vs. OE 22, p = 0.021) all were in favor of MIE. Median ICU stay and operative time did not differ. Neither did overall (OS) nor recurrence-free (RFS) 3-year survival differs significantly (MIE 64% vs. OS OE 49%, MIE 57% vs. RFS OE 53%).
In our institution, MIE appears to produce oncologic and survival results similar to those of OE. Shorter length of stay and less operative blood loss may reduce costs for MIE.
我们比较了微创食管切除术(MIE)与艾弗·刘易斯式开放手术(OE)在治疗局部晚期食管腺癌(EAC)方面的肿瘤学和手术结果。
在2003年至2013年间接受EAC手术的284例患者中,选择153例局部晚期EAC患者,其中74例行MIE,79例行OE[中位年龄,MIE为66岁,OE为63岁(p = 0.009)]。82%的MIE患者和78%的OE患者接受了新辅助治疗。在OE组中,男性占86%,在MIE组中,男性占78%。评估的数据包括肿瘤学、术中及术后数据。
MIE组30天死亡率为3%,OE组为1%;90天死亡率MIE组为4%,OE组为5%。MIE组的并发症发生率为50%,OE组为60%(p = 0.181)。MIE组肺炎发生率为18%,OE组为19%;渗漏率MIE组为7%,OE组为6%;管道坏死MIE组为0,OE组为3%;气道-管道瘘发生率MIE组为3%,OE组为1%。中位失血量(MIE为300 vs. OE为800,p < 0.0001)、总住院时间(MIE为13天 vs. OE为14天,p = 0.040)和获取的淋巴结数量(MIE为20个 vs. OE为22个,p = 0.021)均有利于MIE。中位ICU住院时间和手术时间无差异。3年总生存率(OS)和无复发生存率(RFS)也无显著差异(MIE为64% vs. OS OE为49%,MIE为57% vs. RFS OE为53%)。
在我们的机构中,MIE似乎能产生与OE相似的肿瘤学和生存结果。住院时间较短和手术失血量较少可能会降低MIE的成本。